Shedding light on our prophylactic vaccines’ mechanism of action
September 26, 2017
By Giuseppe Ciaramella, Ph.D.
Chief Scientific Officer, Infectious Diseases, Moderna
When I describe leading infectious disease research efforts at Moderna, I often say it’s a bit like being a kid in a candy shop. We have this amazing, versatile tool in our hands. And we’re pushing the boundaries of this platform technology’s capabilities by exploring a range of options simultaneously – both across therapeutic areas and within therapeutic areas.